Background {#Sec1}
==========

With an estimated incidence of more than 60,000 cases in the USA alone, cancer of the head and neck region is a common malignant disease. In male patients, cancer of the oral cavity and pharynx is the eighth most common cancer type. For 2016, 13,190 patients are estimated to succumb to the disease \[[@CR1]\]. The most prevalent histological subtype in the head and neck region is squamous cell carcinoma (HNSCC), and common risk factors are the concurrent abuse of tobacco and alcohol as well as infections with a high-risk human papillomavirus (HPV) like HPV16 and HPV18. Depending on the causative agent, distinct differences have been recorded with regard to molecular alterations, tumor site, and prognosis of the tumors. While *TP53* mutations are the most common alterations in smoking-related cancers, HPV-associated tumors predominantly harbor *PIK3CA* mutations \[[@CR2]\]. Moreover, patients with HPV-associated tumors tend to be younger, and tumors are more likely to develop in the oropharynx. Notably, these patients also have a better overall survival \[[@CR3]\].

Most patients present in an advanced stage of disease. Surgery or radiation therapy with concurrent chemotherapy are first-line treatment options for HNSCC patients, but local and distant failure is common \[[@CR4]\]. Newer drugs like the anti-EGFR antibody cetuximab have been successfully implemented into the therapeutic portfolio of HNSCC \[[@CR5]\]. Combined with standard platinum-based chemotherapy, they provide a significant overall survival benefit for patients with recurrent or metastatic disease. For the same patient group, immunotherapy agents like the immune checkpoint inhibitor pembrolizumab have recently shown high efficacy \[[@CR6]\]. Based on these results, pembrolizumab has recently been approved by the US Food and Drug Administration (FDA) for patients with recurrent or metastatic HNSCC. Considering the dismal prognosis in the event of metastatic or recurrent disease, such advances in drug therapy are urgently needed \[[@CR7]\].

As yet, no prognostic molecular biomarkers have been established to assist clinicians in stratifying treatment or surveillance options after initial curative treatment. Currently, clinicopathological parameters like lymph node metastasis or tumor stage serve to identify high-risk patients. Additional biomarkers would be of utmost value to influence treatment strategy and surveillance intensity. With regard to emerging immunotherapy options that have an improved safety and side-effect profile, molecular biomarkers could distinguish patient subgroups that would benefit from adjuvant or neoadjuvant therapy. These biomarkers could further be evaluated in conjunction with other newly identified adverse risk factors like delayed time to treatment \[[@CR8]\].

Tissue-based biomarkers have already been established for other tumor entities. In breast carcinoma, the commercially available multi-gene panel assay Oncotype DX^**©**^ estimates risk of recurrence after first-line treatment for early stage breast cancer by analyzing the expression of 21 genes \[[@CR9]\]. Patients who have been identified as high risk based according to the subsequently calculated recurrence score may profit from intensified surveillance or adjuvant chemotherapy. Another promising biomarker approach is the investigation of the methylation status in a tumor sample. Epigenetic regulation is conferred through methylation, and malignant tumors are frequently hyper- or hypomethylated. Depending on the locus, methylation can result in gene transcription or repression \[[@CR10]\]. Methylation analysis has already changed clinical practice for glioblastoma treatment, where promoter methylation of *MGMT* is predictive of response to the drug temozolomide \[[@CR11]\]. So far, this is the only clinically implemented DNA methylation-based predictive biomarker test. DNA methylation can be quantified reliably and reproducibly via microarray, sequencing, or real-time PCR after bisulfite conversion of DNA \[[@CR12]--[@CR14]\]. Moreover, due to the stability of DNA methylation, the methylation status can be easily obtained even from degraded material like formalin-fixed paraffin-embedded (FFPE) tissue \[[@CR15]\], which represents the most common clinically relevant sample material. Thus, studying epigenetic alterations is a promising approach for the development of biomarkers. Several epigenetic biomarkers have been tested in HNSCC, sometimes with conflicting results \[[@CR16]\]. Hypermethylation of *TIMP3* and *CCNA1*, for instance, have been associated with an increased risk of developing second primary tumors \[[@CR17]\]. Hypermethylation of a gene panel in salivary samples prior to treatment was shown to be prognostic of local recurrence and overall survival \[[@CR18]\]. Consequently, epigenetic markers are emerging as prognostic tools in patients with HNSCC.

The paired-like homeodomain transcription factor 3 (*PITX3*), located on chromosome 10q24 \[[@CR19]\], plays an important role in the midbrain dopamine system development, and single-nucleotide polymorphisms within the *PITX3* gene have been associated with Parkinson's disease \[[@CR20]\]. While the role of *PITX3* in the brain development has been well characterized, its contribution to tumorigenesis remains more elusive. It has been found to be hypermethylated in breast cancer tumors \[[@CR21]\]. Recently, Holmes et al. reported that *PITX3* promoter methylation is strongly associated with biochemical recurrence-free survival in prostate cancer patients \[[@CR22]\].

*PITX3* shares a sequence similarity and at least partly redundant function with the paired-like homeodomain 2 (*PITX2*) \[[@CR21], [@CR23]\]. *﻿PITX2* promoter methylation is a well studied prognostic biomarker in various cancers, i.e. prostate, breast, and bil﻿iary tract cancers ﻿\[[@CR24]--[@CR31]\]. Recent studies investigating the methylation status of *PITX2* in HNSCC and lung cancer cohorts found that hypermethylation was associated with improved survival \[[@CR32], [@CR33]\]. An in vitro diagnostic (IVD) test for anthracycline sensitivity in breast cancer patients based on *PITX2* methylation is currently being developed for commercial distribution by the company Therawis GmbH (Munich, Germany). Similar to *PITX2*, the closely related transcription factor *PITX1* plays a role in the embryonal development \[[@CR34]\]. *PITX1* has been found to be predictive of chemosensitivity in a small HNSCC cohort \[[@CR35]\].

Given the need for new prognostic biomarkers for patients with curatively treated HNSCC and the promising results regarding *PITX2* methylation as a biomarker, the methylation status of *PITX3* was investigated in well-annotated HNSCC cohorts.

Methods {#Sec2}
=======

Patients and ethics {#Sec3}
-------------------

The training cohort comprised 326 retrospectively enrolled HNSCC patients treated at the University Hospital Bonn. Clinical data were obtained for the majority of patients. The study was approved by the Institutional Review Board of the University Hospital Bonn, which waived the need for written informed consent. The validation cohort consisted of 528 HNSCC patients analyzed by The Cancer Genome Atlas (TCGA) Research Network (<http://cancergenome.nih.gov/>). All experiments were conducted in accordance with the Helsinki Declaration of 1975.

Sample preparation, DNA extraction, and bisulfite conversion {#Sec4}
------------------------------------------------------------

Freshly cut sections from FFPE blocks were stained with hematoxylin and eosin. The tumor area was annotated and macrodissected from unstained slides for subsequent methylation analysis. The process of DNA extraction and bisulfite conversion was performed using the innuCONVERT Bisulfite All-In-One Kit (Analytik Jena, Germany) as previously reported \[[@CR36]\]. In order to assess HPV status, the surrogate marker p16 was evaluated by immunohistochemistry.

DNA and messenger RNA (mRNA) from samples from the validation cohort were prepared as described by the TCGA Research Network ([www.cancergenome.nih.gov](http://www.cancergenome.nih.gov/)).

*PITX3* quantitative methylation analysis {#Sec5}
-----------------------------------------

For the training cohort, quantitative *PITX3* methylation analysis was performed by means of quantitative real-time PCR (qPCR) with primers and probes as previously described \[[@CR22]\]. The analytical performance of the qPCR assay has been characterized earlier \[[@CR22]\].

For the validation cohort, DNA methylation data were generated by the TCGA Research Network using the Infinium HumanMethylation450 BeadChip (Illumina, Inc., San Diego, CA, USA). HumanMethylation450 data of level 2 were downloaded directly from the TCGA webpage. The data files included background-corrected methylated (bead_M) and unmethylated (bead_U) bead pair summary intensities as extracted by the R package 'methylumi'. The bead pair (cg20023259) in proximity to the locus of the qPCR assay was selected. Methylation values for the bead pair were calculated by the formula 100% × bead_M/(bead_M + bead_U). The position of the qPCR assay and the bead pair cg20023259 within the *PITX3* gene is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Genomic organization and assay position. Genomic organization of the *PITX3* gene and locations of the *PITX3* qPCR assay \[[@CR22]\] and the Infinium HumanMethylation450 BeadChip bead cg20023259. The information was obtained from Ensembl Homo sapiens version GRCh38.p7

*PITX3* mRNA expression analysis {#Sec6}
--------------------------------

The PITX3 mRNA data obtained from the TCGA Research Network were generated by means of the Illumina HiSeq 2000 RNA Sequencing version 2 analysis (Illumina, Inc., San Diego, CA, USA) as described by the TCGA Research Network ([www.cancergenome.nih.gov](http://www.cancergenome.nih.gov/)). PITX3 mRNA expression (normalized counts) data of level 3 were downloaded from the TCGA webpage.

Statistical analysis {#Sec7}
--------------------

Statistical analyses were performed using SPSS, version 24 (SPSS Inc., Chicago, IL, USA). Bivariate correlations were tested using the Spearman rank correlation coefficient (ρ). Overall survival analyses were conducted by Kaplan-Meier and Cox proportional hazards regression analyses. The Mann-Whitney *U* test and one-way analysis of variance (one-way ANOVA) were employed for the comparison of groups. *p* values [\<]{.ul}0.05 were considered significant.

Results {#Sec8}
=======

*PITX3* DNA methylation and mRNA expression in HNSCC tissue {#Sec9}
-----------------------------------------------------------

The results from the validation cohort are entirely based upon data generated by the TCGA Research Network. The *PITX3* locus was highly methylated in tumor tissues from the training and the validation cohort. Histograms of *PITX3* methylation frequencies in both cohorts are shown in Fig. [2a, c](#Fig2){ref-type="fig"}. In the training cohort, methylation data were available for 466 patient samples including 140 normal and 326 tumor tissue samples. The comparison of *PITX3* methylation in tumor and normal adjacent tissue (NAT) revealed a significant difference between tumor tissue (mean 69.0%, median 71.8%) and NAT (mean 32.1%, median 32.3%; *p* \< 0.001; Fig. [2b](#Fig2){ref-type="fig"}). Methylation ranged from 0.79 to 100% in tumor tissue and from 0 to 82.1% in normal tissue. This finding was confirmed in the validation cohort, in which methylation data were available for 578 patient samples including 50 normal and 528 tumor tissue samples. Methylation was significantly different between tissue types (*p* \< 0.001; Fig. [2d](#Fig2){ref-type="fig"}) and ranged from 6.9 to 76.3% in tumor tissue (mean 36.5%, median 35.9%) and from 11.7 to 26.1% in normal tissue (mean 17.1%, median 16.9%). The methylation differences observed between the two analyzed cohorts might be caused by the application of two different technologies: qPCR and Infinium HumanMethylation450K BeadChip.Fig. 2*PITX3* DNA methylation in HNSCC specimens. Frequency of *PITX3* DNA methylation in the training cohort (**a**) comprising 326 HNSCC patients and validation cohort (**b**) including 528 HNSCC patients. Shown are the methylation levels in tumor tissue only. *PITX3* DNA methylation in tumor tissue compared to normal adjacent tissue from the training (**c**) and the validation (**d**) cohort, respectively. Tumor tissue was methylated significantly higher compared to corresponding normal adjacent tissue. *p* values refer to Wilcoxon-Mann-Whitney test

Furthermore, DNA methylation was shown to be inversely correlated with *PITX3* mRNA (*p* = 0.036) in the validation cohort. Interestingly, mRNA levels were also significantly different in tumor (mean 6.55 normalized counts) compared to normal (mean 15.37 normalized counts) tissue (*p* \< 0.001).

Association of *PITX3* DNA methylation with clinico-pathological parameters {#Sec10}
---------------------------------------------------------------------------

Both in the training and validation cohort, *PITX3* DNA methylation was significantly associated with lymph node status (*p* = 0.006 and *p* \< 0.001, respectively). Moreover, a significant methylation difference was found in regard to HPV status in the training cohort. Using p16 as surrogate marker, p16-negative tumors were significantly lower methylated than p16-positive tumors (66.2 vs. 73.7%, *p* = 0.018). This was confirmed in the validation cohort: HPV-associated (p16-positive) tumors were significantly highly methylated than p16-negative tumors (40.0 vs. 33.1%*, p* = 0.015). In addition, a significant difference in methylation was found when analyzing tumor site in both cohorts (training cohort: *p* = 0.023, validation cohort: *p* = 0.017). A detailed analysis of both cohorts can be found in Table [1](#Tab1){ref-type="table"}.Table 1Association of clinicopathological parameters with *PITX3* methylation in HNSCC patients of the training cohort (*n* = 326) and the validation cohort (*n* = 528)Training cohortValidation cohort (TCGA)VariableNo. (%) of patientsMean *PITX3* methylation (%)*p* valueNo. (%) of patientsMean *PITX3* methylation (%)*p* valueAll patients326 (100)69.0528 (100)36.5 Sex0.580.42  Female74 (22.7)68.0142 (26.9)35.6  Male252 (77.3)69.3386 (73.1)36.8 Age (years)0.160.32  Mean62.260.9  Median620.55610.48   *n*  [\<]{.ul} Median132 (40.5)70.3282 (53.4)36.1   *n* \> Median119 (36.5)71.7245 (46.4)36.9  Unknown75 (23.0)1 (0.2) Smoking status0.910.92  Non-smoker25 (7.7)69.8122 (23.1)36.7  Smoker178 (54.6)70.2393 (74.4)36.6  Unknown123 (37.7)13 (2.5) Pack years0.170.60   [\<]{.ul}4092 (28.2)72.0168 (31.8)36.5  \>4046 (14.1)76.0130 (24.6)37.3  Unknown188 (57.7)230 (43.6) Alcohol consumption0.100.37  Yes81 (24.8)74.8352 (66.7)37.0  No47 (14.4)69.8165 (31.3)35.9  Unknown198 (60.7)11 (2.1) Tumor site0.023^a^0.017^a^  Oral cavity50 (15.3)69.0320 (60.6)36.6  Oropharynx139 (42.6)72.081 (15.3)40.2  Hypopharynx22 (6.7)72.810 (1.9)33.6  Larynx95 (29.1)67.0117 (22.2)33.9  Unknown20 (6.1) pT0.800.22  T1/T2160 (49.1)69.8190 (36.0)34.9  T3/T4119 (36.5)69.2276 (52.3)36.5  Unknown47 (14.4)62 (11.7) pN0.006^a^\<0.001^a^  N0128 (39.3)66.3180 (34.1)32.8  N1/2/3173 (53.1)72.0240 (45.5)37.7  Unknown25 (7.7)108 (20.5) p160.013^a^0.015^a^  Negative200 (61.3)66.274 (14)33.1  Positive51 (15.6)73.741 (7.8)40.0  Unknown75 (23.0)413 (78.2) Grade0.400.33  17 (1.8)62.363 (11.9)34.7  2199 (49.9)70.1311 (58.9)36.3  3107 (26.8)68.8125 (23.7)37.5  40 (0)7 (1.3)43.5  Unknown86 (21.6)22 (4.2) Surgical margin0.180.40  Negative225 (69.0)69.7407 (77.1)36.0  Positive41 (12.6)65.660 (11.4)37.6  Unknown60 (18.4)61 (11.6) Second tumor0.070*NA*  Yes38 (11.7)72.7  No140 (42.9)77.9  Unknown148 (45.4)528 (100) Vascular invasion0.0830.072  Yes22 (6.7)63.0124 (23.5)38.4  No170 (52.1)70.1232 (43.9)35.6  Unknown134 (41.1)172 (32.6)Mann-Whitney *U* test for sex, age (dichotomized), smoking status, pT, p16, surgical margin, second tumor, lymphovascular invasion, and pack years; One-way ANOVA for alcohol consumption, lymph node, grade, and tumor site; Spearman's rank correlation for age. Results from the validation cohort are entirely based upon the data generated by the TCGA Research Network: <http://cancergenome.nih.gov/>*NA* data not available^a^significance

Association of *PITX3* DNA methylation with survival {#Sec11}
----------------------------------------------------

Higher *PITX3* DNA methylation analyzed as continuous variable showed a strong trend towards poorer overall survival in the training cohort (Hazard ratio (HR) = 1.01, \[95% confidence interval (95%CI) 1.00--1.02\], *p* = 0.061). *PITX3* DNA methylation levels were subsequently dichotomized using an optimized cut-off (72.5%). *PITX3* DNA hypermethylation was significantly associated with an increased risk of disease-related death in univariate Cox proportional hazards (HR = 1.80, \[95%CI 1.20--2.69\], *p* = 0.005; Table [2](#Tab2){ref-type="table"}) and Kaplan-Meier (*p* = 0.004; Fig. [3a](#Fig3){ref-type="fig"}) analyses. In addition, p16 expression and N category were significantly associated with survival (Table [2](#Tab2){ref-type="table"}). Furthermore, vascular invasion (V) was significantly associated with poor overall survival (HR = 3.51, \[95%CI 1.90--6.47\], *p* \< 0.001).Table 2Univariate and multivariate Cox proportional hazard analysis of overall survival of HNSCC patients in the training cohort (*n* = 307)UnivariateMultivariateVariableHR (95%CI)*p* valueHR (95%CI)*p* value*PITX3* methylation (dichotomized, optimized cut-off 72.5%)1.80 (1.20--2.69)0.005^a^2.28 (1.29--4.00)0.004^a^p16 expression (neg. reference)0.40 (0.20--0.81)0.010^a^0.27 (0.11--0.67)0.005^a^N category1.28 (1.07--1.53)0.008^a^1.27 (0.97--1.67)0.82T category1.14 (0.96--1.36)0.141.33 (1.03--1.72)0.029^a^Nineteen patients from the 326 patients of the cohort were omitted from survival analysis due to missing follow-up data*NA* not analyzed^a^significant feature Fig. 3Overall survival in patients stratified according to *PITX3* DNA methylation. Kaplan-Meier analysis of overall survival in HNSCC patients stratified according to *PITX3* DNA methylation levels in tumor tissue. **a** Training cohort (all patients). **b** Training cohort (p16-negative patients). **c** Validation cohort (all patients). High *PITX3* DNA methylation was associated with an adverse prognosis in both cohorts, in particular in p16-negative patients from the training cohort. A subgroup analysis of p16-negative patients from the validation cohort was not performed due to largely missing data

Interestingly, when performing a subgroup analysis among patients with p16-negative tumors, patients with *PITX3* hypermethylated tumors revealed an HR of 2.44 (\[95%CI 1.44--4.14\], *p* = 0.001) compared to patients with hypomethylated cancers. This finding was confirmed in Kaplan-Meier analysis (*p* = 0.001; Fig. [3b](#Fig3){ref-type="fig"}). No significant survival differences were seen in *PITX3*-stratified patients with HPV-positive tumors. In a multivariate analysis, *PITX3* methylation status added independent prognostic information (HR = 2.28, \[95%CI 1.29--4.00\], *p* = 0.004; Table [2](#Tab2){ref-type="table"}) about the risk of dying. Vascular invasion status was excluded from multivariate analysis due to largely missing data from both cohorts.

The prognostic biomarker performance was validated in the TCGA cohort. Data were dichotomized by means of an optimized cut-off (35.1%). Univariate analysis showed a significant risk of death for patients with hypermethylated tumors (HR = 1.43, \[95%CI 1.05--1.95\], *p* = 0.022). In a multivariate Cox proportional hazard analysis, *PITX3* methylation added significant prognostic information to T and N category for *PITX3* methylation as dichotomized variable (HR = 1.49, \[95%CI 1.02--2.16\], *p* = 0.038; Table [3](#Tab3){ref-type="table"}). However, mRNA expression analyzed as a continuous variable did not reveal any prognostic significance (HR = 1.00, \[95%CI 0.98--1.02\]; *p* = 0.74). The introduction of an optimized cut-off (normalized counts: 13.52) classified 58 patients as PITX3 mRNA expression-positive and 462 patients as negative. Only a trend towards a better prognosis of expression-positive patients was found (HR = 0.59, \[95%CI 0.34--1.03\], *p* = 0.062).Table 3Univariate and multivariate Cox proportional hazard analysis of overall survival of HNSCC patients in the validation cohort from The Cancer Genome Atlas (*n* = 528)UnivariateMultivariateVariableHR (95%CI)*p* valueHR (95%CI)*p* value*PITX3* methylation (dichotomized, optimized cut-off 35.1%)1.43 (1.05--1.95)0.022^a^1.49 (1.02--2.16)0.038^a^N category1.39 (1.14--1.70)0.001^a^1.25 (1.02--1.54)0.035^a^T category1.31 (1.12--1.54)0.001^a^1.28 (1.06--1.56)0.013^a^p16 expression was omitted from analysis due to largely missing data*NA* not analyzed^a^significant feature

Discussion and conclusions {#Sec12}
==========================

Squamous cell cancer of the head and neck region poses a substantial global health burden and affects patients with a history of nicotine and alcohol abuse as well as patients harboring oral infections with high-risk HPV. The disease poses a large health burden worldwide. Surgery and radiotherapy are the mainstay of therapy with curative intent. Recent advantages in reconstructive techniques may help to reduce morbidity after extensive surgery of radiation-induced damage \[[@CR37]--[@CR39]\]. For patients undergoing curative therapy, biomarkers are urgently needed to identify individuals who are likely to experience tumor recurrence or metastasis and subsequent disease-related death. These patients could benefit from intensified surveillance or adjuvant therapy. Moreover, new immunotherapeutic drugs are emerging from which high-risk patients might benefit.

Epigenetic alterations in form of hypo- or hypermethylated DNA are frequent events in cancer. Investigating the DNA methylation status in patients with malignant diseases is a promising approach to establish new biomarkers. In the present study, *PITX3* DNA methylation was analyzed in a well-annotated HNSCC cohort from the University Hospital Bonn. In multivariate analysis, *PITX3* DNA hypermethylation was significantly associated with the risk of death. These results were validated in a HNSCC cohort from the TCGA Research Network. Furthermore, hypermethylation correlated inversely with PITX3 mRNA expression in the TCGA cohort. Although these findings lead to the conclusion that hypermethylation is associated with silencing of the *PITX3* gene, the transcriptional relevance remains unclear. Hypomethylation may result in transcription of the gene; however, the role of *PITX3* in tumorigenesis has not been described. One possible mechanism could be the co-transcription of other genes on chromosome 10q such as suppressor of fused homolog (*SUFU*), which acts as a negative regulator of the hedgehog signaling pathway. Combined loss of *SUFU* and *p53* results in the development of medulloblastomas and rhabdomyosarcoma in mice \[[@CR40]\]. Hedgehog signaling may also play a role in HNSCC tumorigenesis. Hence, the transcription of a negative regulator could result in a reduced tumor growth \[[@CR41]\]. It has previously been shown that HPV infection may result in alteration of the DNA methylome. Therefore, HPV-mediated epigenetic alterations may account for the hypermethylation in HPV-positive tumors described in the present study \[[@CR42], [@CR43]\]. However, *SUFU* and *PITX3* are not located on the immediately neighboring regions of 10q24. It is therefore unclear whether methylation of *PITX3* could have any influence on *SUFU* transcription.

In a rat model for prostate cancer development following exposure to endocrine-disrupting chemicals, *PITX3* was found to be one of several hypomethylated and therefore expressed genes \[[@CR44]\]. While this model cannot serve as a model for HNSCC tumorigenesis, it is an interesting finding and possibly allows for the implication of *PITX3* alteration being an early event in cancer development. This would be in line with the results of Holmes et al., who were able to show that *PITX3* methylation is a strong prognostic marker for biochemical recurrence in localized prostate cancer \[[@CR22]\].

HNSCC display a high genomic instability with a mean of 141 copy number alterations per tumor, including amplification of 10q24 \[[@CR45], [@CR46]\]. Since amplification has been associated with hypermethylation, this might provide an explanation for the observed methylation differences \[[@CR47]\]. Even though the biological function remains unclear for now, *PITX3* DNA methylation status emerges as a promising biomarker particularly for patients with HPV-negative tumors.

In brief, this is the first study to show that the methylation status of *PITX3* is an independent prognostic factor for overall survival in patients with HNSCC. These findings warrant further investigation in a prospective study setting.
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